Trump to make weight-loss drugs cheaper for seniors on Medicare

Berlingske reports on a significant policy initiative by US President Donald Trump aimed at reducing the cost of weight-loss medications for elderly Americans covered by Medicare. The article notes that this move, set to take effect on July 1, specifically targets GLP-1 based drugs, a category that includes prominent medications like Novo Nordisk's Wegovy. The Danish perspective here is implicitly one of interest, given Novo Nordisk's prominent role in this drug class.

“

Trump vil fra 1. juli gøre vægttabsmedicin billigere for ældre, der har sundhedsforsikringen Medicare.

The report details the current and upcoming pricing for Wegovy pills under Medicare, highlighting a planned increase from $149 to $199 per month. It also provides context on Medicare as a health insurance program primarily for individuals aged 65 and older. The article mentions Trump's repeated criticism of high prices for these medications since his return to the presidency.

“

Det drejer sig om vægttabsmedicin baseret på GLP-1-præparater, der efterligner virkningen af naturlige tarmhormoner, som regulerer appetitten.

Furthermore, Berlingske points out a previous agreement made in November between Novo Nordisk and the US administration for lower prices on diabetes and obesity drugs, approximately 11 months after Trump's re-inauguration. This connection suggests a pattern of negotiation and policy focus on these specific medications within the US administration, with potential implications for global pharmaceutical markets and companies like the Danish Novo Nordisk.

“

Amerikanere, der er dækket af Medicare, kan få Wegovy som pille til 149 dollar om måneden.